Pharma

Shockwave Medical Demonstrates Intravascular Lithotripsy's Efficacy for Lower Limb Lesions at VIVA 2024

New clinical data at VIVA 2024 highlights intravascular lithotripsy as a breakthrough treatment for calcified lower limb lesions in peripheral artery disease.

Merck's Keytruda Receives Landmark 30th EU Approval for Two New Indications in Gynecologic Cancers

This latest approval expands Keytruda’s reach to include the treatment of patients with advanced endometrial carcinoma and those with cervical cancer, bolstering options for patients with these hard-to-treat cancers.

AstraZeneca's Wainzua Recommended for EU Approval as New Therapy for Severe Asthma

The drug, Wainzua, specifically targets type 2 inflammation-driven asthma, a form associated with severe, persistent symptoms and significant impairment in quality of life.

Novartis Pays China’s Baiyu $70M Upfront, with $1.1B in Potential Milestones for Small Molecule Cancer Candidate

We discuss the significance of small molecule drugs in oncology, the rise of China’s biotech industry, and the potential market impact of this collaboration.

Roche's New Breast Cancer Drug Itovebi Receives FDA Approval

In a major development, the FDA has approved Roche’s new drug, Itovebi, which offers a promising option for patients with advanced HER2-positive breast cancer.

Stryker Acquires NICO Corporation

In a strategic move to strengthen its portfolio in the neurotechnology space, Stryker has acquired NICO Corporation, a specialist in minimally invasive brain surgery devices.